Home Elementor

Slide Anything shortcode error: A valid ID has not been provided

News

Agilent Completes Acquisition of BIOVECTRA

Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

Learn More

Full service CDMO specializing in biologics, small molecule, nucleic acid modalities, and fill/finish

Our dedicated team leverages microbial fermentation expertise and complex chemistry experience to support our partners’ product development and manufacturing from clinical to commercial stage. We care about your success!

Contact Us

Biologics Manufacturing Excellence

Developing recombinant proteins, plasmid DNA, or antibody fragments in microbial systems? Let us help you accelerate your journey from bench to market.

Contact Us

Small Molecules: From Process Development to Commercial API Manufacturing

Dedication to continuous improvement and ongoing capabilities expansion has made us a valuable long-term partner to our clients.

Contact Us

News

BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing

BIOVECTRA celebrated the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of Prince Edward Island.

Learn More
Previous slide
Next slide

Feature Story

Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.

Agilent Completes Acquisition of BIOVECTRA

  Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities SANTA CLARA, California, September 20, 2024 – Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes […]

Read More…

Read More

Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.

We offer robust microbial fermentation capabilities throughout your products life cycle from pilot to commercial scale.

With extensive HPAPI process development and production experience for small and large molecule APIs, we are here to advance your project.

With core expertise in complex microbial fermentation, we continue to add to our ability to accommodate small-batch, pilot, clinical, and commercial production needs.

We are dedicated to producing quality products and effectively managing client projects by bringing process engineering, project management, quality, and regulatory expertise to all we do.

BIOVECTRA offers a selection of high-quality Bioreagents, available in a variety of package sizes as well as GMP grade, to support your project from research and testing to manufacturing scale operations.

Resources

Explore our educational resources! Whether it is our innovative approach to manufacturing biologics using microbial fermentation or insight into the risk management of capital expansions – it is good to know educational information is available. Our Thought Leadership page is the place to find whitepapers, brochures, webinars, and other materials to enhance your knowledge.

Come. Stay. Grow.

BIOVECTRA is a leading pharma and biotech CDMO seeking people of all skillsets, backgrounds and walks of life to join our diverse and growing team. Located in picturesque Prince Edward Island and Nova Scotia, our communities offer a safe and welcoming place for you to advance your career.